The FDA has accepted Indevus Pharmaceuticals’ new drug application for its long-acting depot preparation of testosterone undecanoate (Nebido) for the treatment of male hypogonadism. The NDA is predicated on data from six clinical studies in which more than 400 patients received at least one dose of the drug, more than 300 of whom were treated for more than 1 year.
The FDA has accepted Indevus Pharmaceuticals’ new drug application for its long-acting depot preparation of testosterone undecanoate (Nebido) for the treatment of male hypogonadism. The NDA is predicated on data from six clinical studies in which more than 400 patients received at least one dose of the drug, more than 300 of whom were treated for more than 1 year.
In total, more than 3,000 injections of the formulation have been given to hypogonadal males during the clinical development program, according to the company. The application includes post-marketing data from safety reporting through June 2007, reflecting the world-wide experience from more than 260,000 injections of the drug.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.